(Moncton, NB) January 27th 2021 – Picomole is excited to announce a new research project in Boston to detect the presence of lung cancer in breath.
Researchers will collect samples using Picomole breath sampling technology, samples will be processed and analyzed in the Picomole laboratory to detect the presence of lung cancer identified through the analysis of Volatile Organic Compounds found in the breath. The research project has received ethics approval and will begin collecting samples in early 2021. Along with ethics approval, a COVID-19 risk assessment has also been carried out to ensure that sample collection using Picomole technology is safe in a COVID-19 environment. The risk assessment has been previously approved by two (2) independent Infection Prevention and Control and Emergency Operations committees.
The research project will be conducted by Principal investigator Dr. Ibiayi Dagogo-Jack as well as co-investigator Dr. Lecia Sequist. Dr. Dagogo-Jack is an oncologist working with Massachusetts General Hospital, and received her Medical Degree from the University of Chicago Pritzker School of Medicine. Dr Sequist is the Director of the Center for Innovation in Early Cancer detection at Massachusetts General Hospital and received her Medical Degree from Harvard Medical School. Both researchers have clinical interest in lung cancer as well as targeted therapies for the treatment of lung cancer.
The study will further refine the accuracy of Picomole’s machine learning model for the detection of lung cancer. The primary objective of the study is to analyze the VOCs in breath of lung cancer patients and non-lung cancer patients to define the infrared absorption spectrum in non-small cell lung cancer (NSCLC) breath specimens and identify cancer-specific breath profiles.
For further information on Picomole or our Breath Sampler, email info@breathebiomedical.com
-30-
